BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants
Phase 1
Completed
- Conditions
- Acute Venous and Arterial Thrombotic and Thromboembolic EventsHealthy Volunteers
- Interventions
- Drug: BAY3018250 Dose 1Drug: BAY3018250 Dose 2Drug: Placebo
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT06619483
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou University of TCM, Guangzhou, Guangdong, China
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States
Active, not recruiting
- Conditions
- Type 2 Diabetes MellitusChronic Kidney Disease
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 150000
- Registration Number
- NCT06608212
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Phase 4
Active, not recruiting
- Conditions
- Diabetic Macular EdemaNeovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 51
- Registration Number
- NCT06591598
- Locations
- 🇨🇿
Fakultní nemocnice Královské Vinohrady - Urologická klinikay, Praha 10, Czechia
🇨🇿Axon Clinical, s.r.o., Praha 5, Czechia
🇭🇺Budapesti Bajcsy-Zsilinszky Korhaz es Rendelointezet, Budapest, Hungary
A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years
Phase 1
Completed
- Conditions
- Acute Venous and Arterial Thrombotic and Thromboembolic EventsHealthy Volunteers
- Interventions
- Drug: BAY3018250 Dose 1Drug: BAY3018250 Dose 2 infusionDrug: PlaceboDrug: BAY3018250 Dose 2 injection
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 39
- Registration Number
- NCT06562985
- Locations
- 🇺🇸
Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 700
- Registration Number
- NCT06522997
- Locations
- 🇬🇷
General Hospital of Athens LAIKO, Athens, Greece
🇬🇷University General Hospital of Heraklion - Department of Paediatrics, Heraklion, Greece
🇯🇵Kasugai Municipal Hospital, Kasugai, Aichi, Japan
A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants
Phase 1
Recruiting
- Conditions
- Healthy VolunteersPain
- Interventions
- Drug: Placebo GelDrug: A solution of 0.9% SalineDrug: A solution of 0.2% SLS
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT06511973
- Locations
- 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care
Completed
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Interventions
- Other: Darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxel
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 106
- Registration Number
- NCT06498921
- Locations
- 🇧🇪
Many locations, Multiple Locations, Belgium
A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO
Completed
- Conditions
- Neovascular Age-related Macular DegenerationRetinal Vein Occlusion
- Interventions
- Drug: anti-VEGF treatment
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1350
- Registration Number
- NCT06495203
- Locations
- 🇨🇦
Bayer, Mississauga, Canada
A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants
Phase 1
Active, not recruiting
- Conditions
- Healthy VolunteersChronic Kidney DiseaseNon-proliferative Diabetic Retinopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 23
- Registration Number
- NCT06487845
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou University of TCM, Guangzhou, Guangdong, China
An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany
Recruiting
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 500
- Registration Number
- NCT06486844
- Locations
- 🇩🇪
Bayer, Wuppertal, Germany
© Copyright 2025. All Rights Reserved by MedPath